Björn Dahlöf

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen et al. · The Lancet · 2002 · 5.4K citations

Medicine, Cardiology, Internal Medicine +13

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Peter Sever, Björn Dahlöf, Neil R Poulter et al. · The Lancet · 2003 · 3.8K citations

Medicine, Cardiology, Pharmacotherapy +14

Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke

Ralph L. Sacco, Hans‐Christoph Diener, Salim Yusuf et al. · New England Journal of Medicine · 2008 · 966 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

Lennart Hansson, Thomas Hedner, Per Lund‐Johansen et al. · The Lancet · 2000 · 902 citations

Pharmacy, Cardiology, Pharmacotherapy +12

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study

Hans‐Christoph Diener, Ralph L. Sacco, Salim Yusuf et al. · The Lancet Neurology · 2008 · 357 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +15